Mechanisms of Reciprocal Interactions between HIV Associated Neuroinflammation and CNS Persistence: Implications in HIV Neuropathogenesis and Cure (R21 Clinical Trial Not Allowed)

The summary for the Mechanisms of Reciprocal Interactions between HIV Associated Neuroinflammation and CNS Persistence: Implications in HIV Neuropathogenesis and Cure (R21 Clinical Trial Not Allowed) grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Mechanisms of Reciprocal Interactions between HIV Associated Neuroinflammation and CNS Persistence: Implications in HIV Neuropathogenesis and Cure (R21 Clinical Trial Not Allowed): The goals of this initiative are to examine mechanisms of reciprocal interactions between HIV-associated neuroinflammation and CNS persistence in the setting of excellent virologic control using novel CNS cell systems, organoid models and single cell technologies

Federal Grant Title:	Mechanisms of Reciprocal Interactions between HIV Associated Neuroinflammation and CNS Persistence: Implications in HIV Neuropathogenesis and Cure (R21 Clinical Trial Not Allowed)
Federal Agency Name:	National Institutes of Health (HHS-NIH11)
Grant Categories:	Education, Health
Type of Opportunity:	Discretionary
Funding Opportunity Number:	RFA-MH-25-181
Type of Funding:	Grant
CFDA Numbers:	93.242, 93.279, 93.853
CFDA Descriptions:	Information not provided
Current Application Deadline:	November 8th, 2024
Original Application Deadline:	November 8th, 2024
Posted Date:	June 14th, 2024
Creation Date:	June 14th, 2024
Archive Date:	December 14th, 2024
Total Program Funding:
Maximum Federal Grant Award:
Minimum Federal Grant Award:
Expected Number of Awards:
Cost Sharing or Matching:	No
Last Updated:	June 14th, 2024

Applicants Eligible for this Grant: State governments - County governments - City or township governments - Special district governments - Independent school districts - Public and State controlled institutions of higher education - Native American tribal governments (Federally recognized) - Public housing authorities/Indian housing authorities - Native American tribal organizations (other than Federally recognized tribal governments) - Nonprofits having a 501 (c) (3) status with the IRS, other than institutions of higher education - Nonprofits that do not have a 501 (c) (3) status with the IRS, other than institutions of higher education - Private institutions of higher education - For-profit organizations other than small businesses - Small businesses - Others (see text field entitled "Additional Information on Eligibility" for clarification.)
Additional Information on Eligibility: Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.
Link to Full Grant Announcement: https://grants.nih.gov/grants/guide/rfa-files/RFA-MH-25-181.html
Grant Announcement Contact: NIH Grants Information
[email protected]
See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.
Similar Government Grants: • Single Source: Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Data Processing...; • Discovery of in vivo Chemical Probes for the Nervous System (R01 Clinical Trial Not Allowe...; • Addressing Methodological Challenges with Clinical Trials of Rapid-Acting Psychotropic Int...; • Optimizing Treatment Strategies for Adult Attention-Deficit Hyperactivity Disorder (ADHD) ...; • National Cooperative Drug/Device Discovery/Development Groups (NCDDG) for the Treatment of...; • Development of Biomarkers for Mental Health Research and Clinical Utilities: (STTR [R41/R4...; • Development of Biomarkers for Mental Health Research and Clinical Utilities (SBIR [R43/R44...; • Pharmacologic Agents and Drugs for Mental Disorders (SBIR [R43/R44])
More Grants from the National Institutes of Health: • The Experimental Therapeutics Clinical Trials Network (ETCTN) Pharmacokinetic Resource Lab...; • The Experimental Therapeutics Clinical Trials Network (ETCTN) Lead Academic Organizations ...; • NIAID Investigator Initiated Program Project Applications (P01 Clinical Trial Not Allowed); • Single Source: Accelerating Medicines Partnership Schizophrenia (AMP SCZ): Data Processing...; • NIAID Resource-Related Research Projects (R24 Clinical Trial Not Allowed)